FNY Partners Fund’s Amicus Therapeutics FOLD Stock Holding History

FNY Partners Fund’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,500	Closed	-$24K	–	770
2017 Q1	$24K	Buy	+3,500	New	+$22.1K	﹤0.01%	903

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FNY Partners Fund's FOLD Position: Q2 2017 in Review

FNY Partners Fund sold out of Amicus Therapeutics (FOLD) in Q2 2017, closing a stake of 3,500 shares — an estimated $24K sold.

FNY Partners Fund first reported a position in FOLD in Q1 2017 and held it in 1 quarter. The position peaked at $24K in Q1 2017. 141 funds tracked by Wall St. Rank hold FOLD as of Q2 2017.

FNY Partners Fund reported no remaining Amicus Therapeutics position as of Q2 2017 after selling out during the quarter.
FNY Partners Fund sold 3,500 Amicus Therapeutics shares in Q2 2017, an estimated $24K.
FNY Partners Fund first reported a position in Amicus Therapeutics in Q1 2017 and held it in 1 quarter.
FNY Partners Fund's Amicus Therapeutics position peaked at $24K in Q1 2017.
141 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.